Evidence map›Paper›PMID 34250480›Full record

ArticleNeuro-oncology advances

Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient.

Matthew McCord, Rimas V Lukas, Christina Amidei, Nathan Demars, Arnold Gelb, Jill Buck, Sean Sachdev, Alexander Feldman, Matthew Tate, Karan Dixit and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Matthew McCordDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Rimas V LukasDepartment of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Christina AmideiDepartment of Neurosurgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Nathan DemarsZiopharm Oncology, Inc., Boston, Massachusetts, USA.
Arnold GelbBristol-Myers Squibb, San Francisco, California, USA.
Jill BuckZiopharm Oncology, Inc., Boston, Massachusetts, USA.
Sean SachdevDepartment of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Alexander FeldmanDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Matthew TateDepartment of Neurosurgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Karan DixitDepartment of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Daniel J BratDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Lawrence JenningsDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Craig HorbinskiDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Northwestern University · USZiopharm Oncology (United States) · USBristol-Myers Squibb (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DNA mismatch repairgliomaIDHimmunotherapy

Identifiers

PMID34250480
PMCPMC8262637
OpenAlexW3138457205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.